ganciclovir

Ganciclovir (2'-Nor-2'-deoxyguanosine) is an ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Triacetyl-ganciclovir is related to ganciclovir. During the commercial production of Ganciclovir, it may be used for toxicity studies and other analytical studies.

Ganciclovir mono-O-acetate, a derivative of Ganciclovir, is an orally active antiviral agent effective against CMV and belongs to the group of nucleoside analogues.

Ganciclovir monophosphonate is a synthetic analog of 2'-deoxy-guanosine which is used to treat or prevent cytomegalovirus (CMV) infections. It inhibits the replication of human CMV with an IC50 value of 0.01 μM and is effective against strains of CMV from human, monkey, mouse, and guinea pig.

Ganciclovir sodium (Cytovene IV sodium) is the sodium salt of Ganciclovir with antiviral activity, especially against cytomegalovirus (CMV) and herpes simplex virus type 1 (HSV-1).

Ganciclovir triphosphate is a synthetic analog of 2'-deoxy-guanosine which is used to treat or prevent cytomegalovirus (CMV) infections. It inhibits the replication of human CMV with an IC50 value of 0.01 μM and is effective against strains of CMV from human, monkey, mouse, and guinea pig.

Ganciclovir triphosphate (GCV-TP) disodium is a synthetic analog of 2'-deoxyguanosine known for its ability to inhibit the replication of human cytomegalovirus (CMV). It works by binding to viral DNA polymerase, disrupting viral DNA synthesis, and is effective against CMV strains from humans, monkeys, rodents, and guinea pigs, with an IC50 of 0.01 μM. Additionally, Ganciclovir triphosphate disodium is utilized in gene-directed enzyme prodrug therapy for cancer inhibition.

Ganciclovir (BW 759) hydrate is a nucleoside analogue that is an orally active antiviral agent with anti-cytomegalovirus activity. Ganciclovir hydrate is also active against members of the herpes group and some other DNA viruses in vitro. Ganciclovir hydrate inhibits the replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28 in vitro. Ganciclovir hydrate also has an IC 50 of 5.2 μM against feline herpesvirus type-1 ( FHV-1 ) and can diffuse into the brain [1] [2] [3].

N-Carbobenzyloxy-L-valinyl-ganciclovir is a useful organic compound for research related to life sciences. The catalog number is T67280 and the CAS number is 194154-40-0.

Isobetanin is a betacyanin that has been shown to enhance vitexin-2-O-xyloside mediated inhibition of proliferation of T24 bladder cancer cells.

Valine-valine-ganciclovir is a peptide.

Ganciclovir-d5 is the deuterated form of Ganciclovir, Ganciclovir is an antiviral. It is used to treat infections caused by viruses. Ganciclovir is used to treat the symptoms of cytomegalovirus (CMV) infection

Valganciclovir hydrochloride (Valganciclovir HCl) is a hydrochloride salt form of valganciclovir, a prodrug form of ganciclovir, a nucleoside analog of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, and viral replication.

Valganciclovir, the L-valyl ester of ganciclovir, is a prodrug effectively converted to ganciclovir in the body, serving as an antiviral medication for cytomegalovirus (CMV) infections. In vitro studies demonstrate that valganciclovir inhibits glycylsarcosine transport mediated by PEPT1 and PEPT2 in Caco-2 and SKPT cells, respectively, with competitive inhibition K(i) values of 1.68±0.30 mM for PEPT1 and 0.043±0.005 mM for PEPT2. Clinical trials indicate valganciclovir's non-inferior efficacy to ganciclovir in pre-emptive therapy for CMV, exhibiting no significant difference in viral clearance rates or toxicity levels between the treatments. Specifically, 89.5% of patients treated with valganciclovir and 83% treated with ganciclovir achieved viral clearance at 28 days (P=0.030 for non-inferiority). Additionally, valganciclovir prophylaxis at 450 mg twice daily prevented CMV reactivation in patients on an alemtuzumab-containing regimen, with none of the 20 patients experiencing reactivation (P=0.004).